High-risk prostate cancer
Initial staging
Intermediate-risk prostate cancer
Post-surgery 18F-JK-PSMA7 PET/CT
Pre-surgery 18F-JK-PSMA7 PET/CT
Journal
European journal of hybrid imaging
ISSN: 2510-3636
Titre abrégé: Eur J Hybrid Imaging
Pays: England
ID NLM: 101724113
Informations de publication
Date de publication:
23 Jan 2023
23 Jan 2023
Historique:
received:
31
10
2022
accepted:
28
12
2022
entrez:
22
1
2023
pubmed:
23
1
2023
medline:
23
1
2023
Statut:
epublish
Résumé
Positron emission tomography/computed tomography (PET/CT) using radiotracers that bind to the prostate-specific membrane antigen (PSMA) is mainly used in biochemical recurring prostate cancer. The aim of our study was to assess the usefulness of We enrolled a total of 10 patients with intermediate- and high-risk PCa diagnosed by multiparametric-MRI followed by systematic and targeted biopsies, eligible for radical prostatectomy with extended lymph node dissection. Clinical team was blind to the results of the pre-surgery All pre-surgery This pilot study indicates that pre-surgery
Sections du résumé
BACKGROUND
BACKGROUND
Positron emission tomography/computed tomography (PET/CT) using radiotracers that bind to the prostate-specific membrane antigen (PSMA) is mainly used in biochemical recurring prostate cancer. The aim of our study was to assess the usefulness of
METHODS
METHODS
We enrolled a total of 10 patients with intermediate- and high-risk PCa diagnosed by multiparametric-MRI followed by systematic and targeted biopsies, eligible for radical prostatectomy with extended lymph node dissection. Clinical team was blind to the results of the pre-surgery
RESULTS
RESULTS
All pre-surgery
CONCLUSION
CONCLUSIONS
This pilot study indicates that pre-surgery
Identifiants
pubmed: 36683076
doi: 10.1186/s41824-022-00161-2
pii: 10.1186/s41824-022-00161-2
pmc: PMC9868215
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2Subventions
Organisme : Walloon region
ID : 7559 Prospect
Informations de copyright
© 2023. The Author(s).
Références
Lancet. 2020 Apr 11;395(10231):1208-1216
pubmed: 32209449
BJU Int. 2022 Jun;129(6):768-776
pubmed: 35166426
Eur Urol. 2023 Jan;83(1):6-9
pubmed: 36280500
Cancers (Basel). 2022 Feb 24;14(5):
pubmed: 35267481
Eur J Hybrid Imaging. 2022 Mar 15;6(1):6
pubmed: 35288807
J Nucl Med. 2020 Jan;61(1):6-12
pubmed: 31732677
Eur Urol. 2017 Jul;72(1):84-109
pubmed: 28126351
BJU Int. 2022 Sep 7;:
pubmed: 36069585
Eur J Nucl Med Mol Imaging. 2021 Dec;48(13):4483-4494
pubmed: 34120201
Eur J Nucl Med Mol Imaging. 2021 May;48(5):1626-1638
pubmed: 33604691
Cancers (Basel). 2022 Mar 14;14(6):
pubmed: 35326629
Mol Imaging Biol. 2015 Aug;17(4):575-84
pubmed: 26013479
EJNMMI Res. 2019 Jul 25;9(1):66
pubmed: 31346821
J Nucl Med. 2020 Feb;61(2):202-209
pubmed: 31324713
Mol Imaging Biol. 2021 Apr;23(2):277-286
pubmed: 33006028
EJNMMI Res. 2018 Nov 6;8(1):97
pubmed: 30402779